HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab

Overview of attention for article published in Pathology & Oncology Research, April 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,930 followers.

RT @FrontPartners: Researchers from @semmelweishu, @imed_tweets & @harvardmed, including POR Journal Editors Andrea Ladanyi and Jozef Dudas…

15 Jun 2022

Reply Repost Favourite

Researchers from @semmelweishu, @imed_tweets & @harvardmed, including POR Journal Editors Andrea Ladanyi and Jozef Dudas, investigate mechanisms underlying #immune checkpoint inhibitor resistance in #melanoma patients. Read and download the full text!

15 Jun 2022

Reply Repost Favourite

HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab by Andrea Ladányi https://t.co/i83uZofKZW

09 May 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.